NASDAQ:RNTX - Nasdaq - US00887A2042 - Common Stock - Currency: USD
NASDAQ:RNTX (5/2/2025, 8:21:40 PM)
1.82
+0.18 (+10.98%)
The current stock price of RNTX is 1.82 USD. In the past month the price increased by 7.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
REIN THERAPEUTICS INC
12407 N. Mopac Expy., Suite 250 #390
Austin TEXAS US
Employees: 11
Phone: 17378021989
The current stock price of RNTX is 1.82 USD. The price increased by 10.98% in the last trading session.
The exchange symbol of REIN THERAPEUTICS INC is RNTX and it is listed on the Nasdaq exchange.
RNTX stock is listed on the Nasdaq exchange.
8 analysts have analysed RNTX and the average price target is 10.2 USD. This implies a price increase of 460.44% is expected in the next year compared to the current price of 1.82. Check the REIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
REIN THERAPEUTICS INC (RNTX) has a market capitalization of 40.02M USD. This makes RNTX a Nano Cap stock.
REIN THERAPEUTICS INC (RNTX) currently has 11 employees.
REIN THERAPEUTICS INC (RNTX) has a support level at 1.71 and a resistance level at 1.82. Check the full technical report for a detailed analysis of RNTX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RNTX does not pay a dividend.
REIN THERAPEUTICS INC (RNTX) will report earnings on 2025-05-20.
REIN THERAPEUTICS INC (RNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.78).
The outstanding short interest for REIN THERAPEUTICS INC (RNTX) is 0.71% of its float. Check the ownership tab for more information on the RNTX short interest.
ChartMill assigns a technical rating of 3 / 10 to RNTX.
ChartMill assigns a fundamental rating of 2 / 10 to RNTX. While RNTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months RNTX reported a non-GAAP Earnings per Share(EPS) of -3.78.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.06% | ||
ROE | -30.71% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to RNTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.